Inicio › Cáncer de vejiga › Massachusetts › Boston
Ensayos clínicos de Cáncer de vejiga en Boston, MA
26 estudios para Cáncer de vejiga buscan participantes en centros de Boston y alrededores (a unos 30 millas). Abra un estudio para ver quién puede participar y cómo contactar con el equipo.
Texto oficial del estudio (inglés)
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)
ReclutandoFase 3
- Dana Farber Cancer Institute ( Site 0783), Boston
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
ReclutandoFase 2
- Massachusetts General Hospital Cancer Center, Boston
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
ReclutandoFase 1
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
ReclutandoFase 1
- Massachusetts General Hospital, Boston
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
ReclutandoFase 2
- Dana-Farber Cancer Institute - Oncology Department, Boston
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
ReclutandoFase 1
- Massachusetts General Hospital, Boston
Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial
ReclutandoFase 2
- Tufts Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Acupuncture and Exercise for EV-Pembro-Induced Peripheral Neuropathy
Reclutando
- Dana Farber Cancer Institute, Boston
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
ReclutandoFase 3
- Massachusetts General Hospital Cancer Center, Boston
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
ReclutandoFase 3
- Massachusetts General Hospital, Boston
Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy
ReclutandoFase 3
- Brigham and Women's Hospital, Boston
Patient-Centered Surgical Prehabilitation
ReclutandoSe aceptan voluntarios sanos
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors
ReclutandoFase 1
- Dana-Farber Cancer Institute, Boston
Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC
ReclutandoFase 2
- Brigham and Women's Hospital, Boston
Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer
ReclutandoFase 2
- Brigham and Women's Hospital, Boston
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
ReclutandoFase 1/2
- Massachusetts General Hospital Cancer Center, Boston
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
ReclutandoFase 1/2
- Brigham and Women's Hospital, Boston
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
ReclutandoFase 2/3
- Local Institution - 0195, Boston
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
ReclutandoFase 2
- Tufts Medical Center, Boston
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC
ReclutandoFase 3
- Research Site, Boston
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
ReclutandoFase 1
- Massachusetts General Hospital, Boston
- Brigham & Women's Hospital, Boston
- Beth Israel Deaconess Medical Center,East Campus Research Pharmacy, Boston
- y 2 más
Management of Cisplatin-Ineligible Patients With Metastatic Bladder Cancer and The Role of Geriatric Assessments
ReclutandoEstudio observacional
- Dana-Farber Cancer Institute, Boston
CONFIRM: Magnetic Resonance Guided Radiation Therapy
Reclutando
- Brigham & Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Sacituzumab Govitecan Plus EV in Metastatic UC
ReclutandoFase 1/2
- Dana Farber Cancer Institute, Boston
Bladder Fiducial Markers and Multiparametric-MRI (Mp-MRI) to Optimize Bladder Chemo-radiotherapy
Reclutando
- Harvard School of Medicine/Massachusetts General Hospital (MGH), Boston
Alvimopan Versus Placebo in Patients Undergoing Radical Cystectomy on an Enhanced Recovery Protocol
ReclutandoFase 3
- Brigham and Women's Hospital, Boston
Más información sobre Cáncer de vejiga en MedlinePlus
Ensayos de Cáncer de vejiga en otras ciudades
- New York City, NY36 estudios
- Nashville, TN31 estudios
- Houston, TX31 estudios
- Dallas, TX27 estudios
- Washington, DC26 estudios
- Los Angeles, CA25 estudios
- Baltimore, MD24 estudios
- Philadelphia, PA23 estudios
- Edison, NJ23 estudios
- St. Louis, MO22 estudios
- Chicago, IL21 estudios
- Seattle, WA21 estudios
Otros estudios en Boston
- Cáncer de seno110 estudios
- Cáncer (todos los tipos)90 estudios
- Cáncer de pulmón de células no pequeñas87 estudios
- Cáncer de pulmón63 estudios
- Cáncer del colon y del recto62 estudios
- Cáncer de ovario62 estudios
- Cáncer metastásico61 estudios
- Cáncer de próstata56 estudios
- Cáncer de endometrio51 estudios
- Depresión50 estudios
- Fallo cardíaco46 estudios
- Mieloma múltiple45 estudios
De ClinicalTrials.gov, datos obtenidos el 15 nov 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.